

**Table 1. Patient demographics and clinical characteristics during baseline**

	<b>POS (n=10)</b>	<b>SGS (n=1)</b>	<b>PGTCS (n=3)</b>	<b>Total (N=13)</b>
<b>Age,<sup>a</sup> years</b>				
Mean (SD)	47.5 (15.1)	51.0 (NA)	37.3 (7.6)	45.2 (14.2)
Median (min, max)	47.5 (19, 68)	51.0 (51, 51)	39.0 (29, 44)	44.0 (19, 68)
<b>Female, n (%)</b>	5 (50.0)	1 (100.0)	1 (33.3)	6 (46.2)
<b>Race, n (%)</b>				
Caucasian	9 (90.0)	1 (100.0)	2 (66.7)	11 (84.6)
Black/African American	1 (10.0)	0 (0.0)	0 (0.0)	1 (7.7)
Asian	0 (0.0)	0 (0.0)	1 (33.3)	1 (7.7)
<b>Number of ASMs, n (%)</b>				
EIASMs <sup>b</sup>	1 (10.0)	0 (0.0)	0 (0.0)	1 (7.7)
Non-EIASMs	7 (70.0)	1 (100.0)	2 (66.7)	9 (69.2)
Total	8 (80.0)	1 (100.0)	2 (66.7)	10 (76.9)

<sup>a</sup>Age at Date of Informed Consent/Assent

<sup>b</sup>EIASMs include patients who took at least one EIASM at baseline (defined as carbamazepine, oxcarbazepine, and phenytoin)

EIASM, enzyme-inducing anti-seizure medication; POS, partial-onset seizures; PGTCS, primary generalized tonic-clonic seizures; SD, standard deviation; SGS, secondarily generalized seizures